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Abstract: Staphylococcus aureus (S. aureus) is a leading cause of skin and soft-tissue infections (SSTIs)
in the community. In this study, we characterized a collection of 34 S. aureus from SSTIs in ambulatory
patients in Portugal and analyzed the presence of Panton–Valentine leucocidin (PVL)-encoding genes
and antibiotic-resistance profile, which was correlated with genetic determinants, plasmid carriage,
and clonal lineage. Nearly half of the isolates (15, 44.1%) were methicillin-resistant Staphylococcus
aureus (MRSA) and/or multidrug resistant (MDR). We also detected resistance to penicillin (33/34,
97.1%), fluoroquinolones (17/34, 50.0%), macrolides and lincosamides (15/34, 44.1%), aminoglyco-
sides (6/34, 17.6%), and fusidic acid (2/34, 5.9%), associated with several combinations of resistance
determinants (blaZ, erm(A), erm(C), msr(A), mph(C), aacA-aphD, aadD, aph(3′)-IIIa, fusC), or mutations
in target genes (fusA, grlA/gyrA). The collection presented a high genetic diversity (Simpson’s index
of 0.92) with prevalence of clonal lineages CC5, CC22, and CC8, which included the MRSA and also
most MDR isolates (CC5 and CC22). PVL-encoding genes were found in seven isolates (20.6%), three
methicillin-susceptible Staphylococcus aureus (MSSA) (ST152-agrI and ST30-agrIII), and four MRSA
(ST8-agrI). Plasmid profiling revealed seventeen distinct plasmid profiles. This work highlights the
high frequency of antimicrobial resistance and PVL carriage in SSTIs-related S. aureus outside of the
hospital environment.
Keywords: Staphylococcus aureus; skin and soft-tissue infections; antibiotic resistance; clonal lineages;
plasmids; Panton–Valentine leucocidin
1. Introduction
Staphylococcus aureus (S. aureus) is a major human pathogen responsible for a wide
range of infections both in hospitals and in the community. It is one of the main causes
of severe nosocomial infections such as bacteremia and infective endocarditis and in the
community is a frequent cause of skin and soft-tissue infections (SSTIs) [1]. Besides their
potential severity, infections caused by S. aureus are usually difficult to treat due to the
frequent acquisition of antimicrobial resistance determinants. In the last decades, there has
been an emergence and dissemination of methicillin-resistant S. aureus (MRSA) as well as
of multidrug-resistant (MDR) strains [2,3]. Consequently, MRSA are now included in the
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World Health Organization (WHO) list of high-priority bacteria for development of new
drugs [4].
S. aureus is the most frequent pathogen associated with SSTIs, which can range from
minor or superficial infections such as impetigo to life-threating infections such as necrotiz-
ing fasciitis [5]. Topical antibiotics that are often used for the prevention or treatment of
milder infections include mupirocin, fusidic acid, neomycin, and bacitracin [6,7]. The use
of some of these topical antibiotics is particularly relevant in the community/ambulatory
settings, where they may not require medical prescription. Other antibiotics for systemic
use, such as clindamycin, trimethoprim-sulfamethoxazole, tetracyclines, and linezolid, are
also indicated for treatment of severe forms of SSTIs caused by S. aureus [6,8]. The frequency
of antibiotic-resistant S. aureus isolates associated with SSTIs is rising worldwide [9–12],
particularly to fusidic acid and mupirocin, which is probably linked with the widespread
use of these antibiotics [3].
Resistance to antibiotics in S. aureus can be mediated by several mechanisms, such as
antibiotic modification or degradation, target mutation, or antibiotic efflux. Resistance to
penicillins can occur by inactivation of the antibiotic molecule through the action of the
β-lactamase BlaZ. The blaZ gene occurs frequently in S. aureus clinical isolates. Resistance
to penicillins and other β-lactams, with the exception of fifth-generation cephalosporins, is
mediated by the acquisition of the mecA gene, which is part of the mobile genetic element
SCCmec (staphylococcal cassette chromosome mec) and encodes for an additional penicillin-
binding protein, PBP2a, with low affinity for the β-lactam antibiotics [3]. Resistance
to macrolides and lincosamides can occur through several mechanisms, including the
acquisition of rRNA methylases-encoding erm genes that methylate the binding site of the
antibiotics [3]. Resistance to aminoglycosides is associated with acquisition of several genes,
like aacA-aphD or aadD that encode enzymes that modify the antibiotic molecule rendering it
inactive [3]. Resistance to fluoroquinolones is usually linked to the occurrence of mutations
in the quinolone-resistant determining region (QRDR) of the grlA/B and gyrA/B genes
that encode the DNA topoisomerase IV and DNA gyrase, respectively. Fluoroquinolone
resistance can also be conveyed by overexpression of chromosomally-encoded efflux pump
genes such as norA/B/C and mepA [13]. Resistance to fusidic acid can be achieved by the
acquisition of the fusB/C genes that encode ribosomal protection proteins or by mutations
in the fusA gene [3].
S. aureus produces several virulence factors, including toxins, proteins associated
with immune evasion, and tissue-degrading enzymes [1]. The cytotoxin Panton–Valentine
leucocidin (PVL), encoded by the genes lukF-PV and lukS-PV carried on bacteriophage
ϕSa2, is a two-component pore-forming protein that has been strongly associated with S.
aureus isolates causing skin infections in the community and with necrotizing pneumo-
nia [1]. Nevertheless, the role of PVL in S. aureus infection pathogenesis is still not fully
elucidated [14]. The S. aureus accessory gene regulator (agr) locus regulates the expression
of several virulence factors like cell-wall-associated and extracellular proteins, contributing
to infection severity and persistence. The polymorphism of the agr locus allows the clas-
sification of S. aureus in four predominant agr types (I to IV), that may differ in terms of
infection type, carriage of virulence factors, and temporal patterns of autoinduction [15].
Most antimicrobial resistance and virulence genes of S. aureus are located on mo-
bile genetic elements (MGEs) such as plasmids, bacteriophages, pathogenicity islands,
transposons, integrative conjugative elements (ICEs), integrons, and staphylococcal chro-
mosome cassettes (SCCs), which make up to 15–20% of its genome [16]. The acquisition
of antimicrobial resistance by S. aureus is mostly due to horizontal gene transfer (HGT),
and plasmids have been identified as one of the main responsible for the dissemination of
resistance genes [17].
Several studies have evaluated the main clones of MRSA circulating both in hospitals
and in the community in Portugal, a country with a high prevalence of MRSA [18–22].
However, there have been fewer studies focusing on S. aureus, both methicillin-susceptible
Staphylococcus aureus (MSSA) and MRSA causing SSTIs. The aim of this work was to per-
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form a phenotypic and genotypic characterization of a collection of S. aureus isolated from
SSTIs in ambulatory patients and to assess their virulence determinants and susceptibility
to the main antibiotics used in SSTI therapeutics, correlating their resistance profile to
genetic determinants and identifying their main mechanisms of dissemination among S.
aureus strains.
2. Results
2.1. Antimicrobial Susceptibility Profile and Correlation with Resistance Determinants
The antimicrobial susceptibility profile of the 34 isolates is described in Table 1. Resis-
tance to penicillin was detected in 97.1% (33/34) of the isolates, and 44.1% (15/34) were
MRSA (mecA+ and cefoxitin resistant). We have also observed resistance to the fluoro-
quinolones ciprofloxacin and moxifloxacin (50.0%, 17/34), erythromycin (44.1%, 15/34),
clindamycin (35.3%, 12/34) either constitutive (2.9%, 1/34) or inducible (32.4%, 11/34),
kanamycin (17.6%, 6/34), tobramycin (14.7%, 5/34), amikacin (8.8%, 3/34), gentamycin
(2.9%, 1/34), and fusidic acid (5.9%, 2/34). Fifteen isolates (44.1%) were MDR, mainly
resistant to β-lactams, fluoroquinolones, macrolides, and lincosamides. All isolates were
susceptible to tetracyclines, tigecycline, rifampicin, trimethoprim-sulfamethoxazole, line-
zolid, chloramphenicol, retapamulin, and quinupristin-dalfopristin. All MRSA isolates
were susceptible to ceftaroline. Only one isolate was susceptible to all antibiotics tested.
Although no breakpoints or epidemiological cut-off values are established by the European
Committee on Antimicrobial Susceptibility Testing (EUCAST) for bacitracin or neomycin
(for 30 µg discs), one isolate showed no inhibition zone toward each of these topical an-
tibiotics. The presence of antibiotic-resistance determinants was confirmed for all isolates
presenting phenotypic resistance (Table 1). The blaZ gene was detected in all isolates
resistant to penicillin. All isolates showing resistance to cefoxitin harbored the mecA gene.
Mutations in QRDR regions of grlA and gyrA genes were found in different combinations in
all the representative fluoroquinolone resistant isolates screened. Resistance to macrolides
and lincosamides was associated with erm(A), erm(C), msr(A), and/or mph(C). Resistance
to aminoglycosides was mainly linked to the aadD gene. For the two isolates resistant to
fusidic acid, one harbored the fusC gene, whereas the other carried three mutations in the
fusA gene.
Table 1. Antimicrobial resistance phenotypes of the 34 S. aureus included in this study and correlation with resis-
tance determinants.
Class Antibiotic Resistant Isolates (%) Resistance Determinants(No. Isolates); [Mutations]
β-lactams
PEN 33 (97.1%) blaZ (33)
mecA (15)CXI 15 (44.1%)
Fluoroquinolones CIP 17 (50%) Mutations in GrlA [S80Y, E84G,
S80F] and GyrA [S84L, E88K]MOX 17 (50%)
Macrolides/Lincosamides
ERY 15 (44.1%) erm(A) (9), erm(C) (7)
msr(A) (4), mph(C) (3)CLI 12 (35.3%)
Aminoglycosides
KAN 6 (17.6%)
aadD (4), aacA-aphD (1)
aph(3′)-IIIa (1)
TOB 5 (14.7%)
AMI 3 (8.8%)
GEN 1 (2.9%)
Fusidanes FUS 2 (5.9%)
fusC (1)
FusA mutations
[A71V, H457Q, G476C]
PEN: penicillin; CXI: cefoxitin; ERY: erythromycin; CLI: clindamycin; CIP: ciprofloxacin; MOX: moxifloxacin; KAN: kanamycin; GEN:
gentamycin; TOB: tobramycin; AMI: amikacin; and FUS: fusidic acid.
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2.2. Efflux Activity
The presence of increased efflux activity in the 34 isolates was assessed by different
approaches. The minimum inhibitory concentrations (MICs) of ethidium bromide (EtBr)
for the entire collection ranged from 2 to 16 µg/mL with a unimodal distribution (data
not shown). Eleven isolates presented an EtBr MIC of 16 µg/mL, suggesting increased
efflux activity in those isolates. In addition, these 11 isolates were also resistant to fluoro-
quinolones, a class of antibiotics that is substrate of the main efflux pumps in S. aureus [13].
To verify the presence of an efflux-mediated resistance in these 11 isolates, the EtBr and
ciprofloxacin (CIP) MICs were determined in the presence of the known efflux inhibitors
(EIs) thioridazine (TZ) and verapamil (VER) and compared to their original values (Table 2).
A significant decrease (four- to eight-fold) in EtBr MICs was observed for all isolates but
one, confirming the presence of increased efflux activity in these isolates. However, none
of the isolates carried the plasmid-encoded qacA/B or smr genes, which code for the efflux
pumps QacA/B and Smr, respectively, responsible for the extrusion of EtBr and several bio-
cides. These results indicate that the increased efflux activity present in these isolates may
be driven by chromosomally-encoded efflux pumps, like NorA, which extrudes EtBr and
biocides but also several fluoroquinolones like ciprofloxacin and norfloxacin [13]. The effect
of EIs on CIP MICs was less significant, with MIC reductions of two-fold for the majority of
the isolates. This result does not exclude the presence of increased efflux activity associated
with fluoroquinolone resistance, since these isolates harbor mutations in the QRDR of grlA
and gyrA genes, which are responsible for conferring high-level fluoroquinolone resistance
and thus may be hindering the screening of efflux activity associated with resistance to
these antibiotics [23].
Table 2. The effect of the efflux inhibitors thioridazine and verapamil on ethidium bromide and
ciprofloxacin MICs for selected S. aureus isolates.
Isolate
MIC (µg/mL)
EtBr EtBr + TZ EtBr +VER CIP CIP + TZ CIP + VER
BIOS-H4 16 4 2 16 16 16
BIOS-H7 16 8 8 512 256 256
BIOS-H8 16 8 4 512 256 256
BIOS-H10 16 8 4 512 256 256
BIOS-H11 16 4 2 256 128 128
BIOS-H14 16 4 2 128 64 64
BIOS-H19 16 4 2 512 256 256
BIOS-H23 16 4 4 256 128 256
BIOS-H24 16 2 2 32 16 16
BIOS-H31 16 4 2 512 128 128
BIOS-H33 16 4 2 512 256 256
MIC: minimum inhibitory concentration; EtBr: ethidium bromide; CIP: ciprofloxacin; TZ: thioridazine; VER:
verapamil. Bold-type numbers indicate MIC reductions ≥ four-fold in the presence of EIs when compared to the
original MIC values.
2.3. Main Clonal Lineages and Genetic Diversity of the S. aureus Isolates
Analysis of SmaI-macrorestriction profiles revealed the presence of 15 pulsed-field
gel electrophoresis (PFGE) types (A to O) and 18 subtypes (Figure 2) among the collection
studied. The three most common profiles, PFGE types G, N, and E, are represented by
seven, five, and four isolates, respectively. An isolate representative of each PFGE type
was selected for typing by multilocus sequence typing (MLST). Fourteen sequence types
(STs) were identified belonging to 10 clonal complexes. The clonal complexes identified
were CC5 (ST5, ST105, and the newly identified ST6531, which is a single-locus variant
(SLV) of ST5), CC8 (ST8, ST72), CC152 (ST152), CC30 (ST30), CC7 (ST7), CC97 (ST97), CC15
(ST15), CC25 (ST25), CC22 (ST22), and CC45 (ST278). We also detected a newly identified
singleton, ST6564. In general, each ST identified was associated with a single PFGE type,
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except for ST5 (CC5), associated with PFGE types F and D and ST8 (CC8) associated with
PFGE types C and E. The most common PFGE types were linked to ST105 (CC5), ST22
(CC22), and ST8 (CC8). The Simpson’s index of diversity (SID), calculated based upon
the PFGE SmaI-macrorestriction profiles, revealed a highly diverse S. aureus population
(SID = 0.92, CI: 0.87–0.98).
2.4. Correlation of Strain Lineage with agr Typing and PVL Carriage
The agr typing of the S. aureus isolates identified agrI as the predominant type, which
was detected in 20 out of the 34 isolates (58.8%), followed by agr type II, identified in 13/34
(38.2%) isolates, and agr type III, observed in a single isolate (1/34, 2.9%). No isolate of agr
type IV was identified. The PVL-encoding genes lukS-lukF were detected in seven isolates
(20.6%), corresponding to three MSSA (3/19, 15.8%) and four MRSA (4/15, 26.7%), all
classified as agr type I or III.
As shown in Figure 2, an association was observed between S. aureus clonal lineages
ST8 (CC8), ST25 (CC25), ST22 (CC22), ST7 (CC7), ST278 (CC45), ST97 (CC97) and ST152
(CC152) and agr type I, whereas clonal complexes CC5 and CC15 were linked to agr type II,
and the singe isolate harboring agr type III belonged to ST30 (CC30). The newly identified
singleton ST6564 belongs to agr type I.
Carriage of PVL was associated with MRSA belonging to ST8 (CC8) and MSSA
assigned to ST152 (CC152) or ST30 (CC30).
2.5. Correlation of Strain Lineage with Antimicrobial Resistance and Plasmid Profiles
Analysis of the methicillin resistance status and clonal lineage showed that the MRSA
isolates identified in the collection were restricted to the clonal complexes CC22, CC8 (ST8),
and CC5 (ST5 and ST105) (Figure 1). Most isolates from ST22 and clonal lineages of the
CC5 presented MDR phenotypes (Figure 1).
Antibiotics 2021, 10, x  8 of 17 
 
2.4. Correlation of Strain Lineage with agr Typing and PVL Carriage 
The agr typing of the S. aureus isolates identified agrI as the predominant type, which 
was detected in 20 out of the 34 isolates (58.8%), followed by agr type II, identified in 13/34 
(38.2%) isolates, and agr type III, observed in a single isolate (1/34, 2.9%). No isolate of agr 
type IV was identified. The PVL-encoding genes lukS-lukF were detected in seven isolates 
(20.6%), corresponding to three MSSA (3/19, 15.8%) and four MRSA (4/15, 26.7%), all 
classified as agr type I or III. 
As sho n in Figure 1, an association as observed bet een S. aureus clonal lineages 
ST8 (CC8), ST25 (CC25), ST22 (CC22), ST7 (CC7), ST278 (CC45), ST97 (CC97) and ST152 
( 152) and agr type I, whereas clonal complexes C5 and C15 were linked to agr type 
II, and the singe isolate harboring agr type III belonged to ST30 (CC30). The ewly 
identified singleton ST6564 belongs to agr type I. 
i  f   i t  it   l i  t   ( )   
i       . 
. . rrel ti  f tr i  i e e it  ti i r i l esist e  l s i  r files 
l sis f t  t icilli  r sist c  st t s  cl l li  s  t t t   
isolates identified in the collection were restricted to the clonal complexes CC22, CC8 
(ST8), and CC5 (ST5 and ST105) (Figure 2). Most isolates from ST22 and clonal lineages of 
the CC5 presented MDR phenotypes (Figure 2). 
 
Figure 2. Relation of clonal lineages identified amongst the S. aureus associated with SSTIs in ambulatory patients 
determined using PHYLOViZ software and correlation with (A) methicillin resistance status, PVL carriage, and agr type; 
and (B) MDR phenotypes and plasmid profile. In panel A, MRSA isolates are displayed in orange whereas MSSA isolates 
are shown in light blue. In panel B, MDR isolates are presented in red, while non-MDR isolates are shown in green. 
The majority of the S. aureus isolates studied carried plasmids (28/34, 82.4%), with 19 
isolates (55.9%) carrying one plasmid, eight isolates (23.5%) carrying two plasmids, and 
only one isolate (2.9%) carrying three plasmids. Large plasmids (≥23 kb) were present in 
most isolates (24/34, 70.6%), alone or in combination with medium or smaller plasmids 
(10 kb or ≤3 kb). Isolates with large plasmids harbor, in general, a higher number of 
resistance determinants than those carrying small or no plasmids (Figure 1). 
Seventeen plasmid profiles were identified, designated P1 to P17 (Figure 1). For 
strains carrying a single plasmid, these profiles were defined after restriction with EcoRI–
profiles P1 to P10. The most frequent profile, P1, is represented by a single large plasmid 
(>23 kb), identified in six isolates, five of which belonging to ST105 (CC5). All isolates with 
1. Relation of clonal lineag s identified amongst the S. aureus associated with SSTIs n ambulatory patients determined
using PHYLOViZ software and correlatio with (A) methicillin resistan e statu , PVL carriage, and ag type; and (B) MDR
phenotypes and plasmid profile. In panel (A), MRSA isolates are displayed in orange whereas MSSA isolates are shown in
light blue. In panel (B), MDR isolates are presented in red, while non-MDR isolates are shown in green.
Antibiotics 2021, 10, 345 6 of 15
Antibiotics 2021, 10, x  6 of 17 
 
 
Figure 1. SmaI-PFGE macrorestriction profile analysis of the S. aureus isolates associated with SSTIs in ambulatory patients and corresponding clonal lineages as 
determined by MLST and their correlation with PVL carriage and agr types, plasmid profiles, and phenotypic and genotypic resistance traits. The pairs of isolates 
Figure 2. SmaI-PFGE macrorestriction profile analysis of the S. aureus isolates associated with SSTIs in ambulatory patients and corresponding clonal lineages as determined by MLST and
their correlation with PVL carriage and agr types, plasmid profiles, and phenotypic and genotypic resistance traits. The pairs of isolates recovered from different anatomical sites of the
same patient are marked by (A) to (F), where each letter corresponds to a different patient. The dendrogram was built using Bionumerics and the UPGMA algorithm, using Dice coefficient,
and an optimization of 0.5% and tolerance of band of 1%. The dashed lines correspond to the similarity criteria for considering isolates belonging to the same PFGE type (≥81%) or
subtype (≥97%). Isolates sharing the same PFGE type or subtype were considered as belonging to the same sequence type (ST). The isolates subjected to MLST are indicated in bold-type.
Each plasmid profile corresponds to a unique pattern of undigested and/or EcoRI-digested plasmids. CC: clonal complex; ST: sequence type; PFGE: pulsed-field gel electrophoresis; PVL:
Panton–Valentine leucocidin; PEN: penicillin; CXI: cefoxitin; ERY: erythromycin; CLI: clindamycin; CIP: ciprofloxacin; MOX: moxifloxacin; KAN: kanamycin; GEN: gentamycin; TOB:
tobramycin; AMI: amikacin; and FUS: fusidic acid. Resistance mutations: GrlA1: S80Y; GrlA2: S80F; GrlA3: S80Y, E84G; GyrA1: S84L; GyrA2: E88K; FusA1: A71V, H547Q, G476C.
Antibiotics 2021, 10, 345 7 of 15
The majority of the S. aureus isolates studied carried plasmids (28/34, 82.4%), with
19 isolates (55.9%) carrying one plasmid, eight isolates (23.5%) carrying two plasmids, and
only one isolate (2.9%) carrying three plasmids. Large plasmids (≥23 kb) were present in
most isolates (24/34, 70.6%), alone or in combination with medium or smaller plasmids
(10 kb or ≤3 kb). Isolates with large plasmids harbor, in general, a higher number of
resistance determinants than those carrying small or no plasmids (Figure 2).
Seventeen plasmid profiles were identified, designated P1 to P17 (Figure 2). For strains
carrying a single plasmid, these profiles were defined after restriction with EcoRI–profiles
P1 to P10. The most frequent profile, P1, is represented by a single large plasmid (>23 kb),
identified in six isolates, five of which belonging to ST105 (CC5). All isolates with this
plasmid profile are MDR and carry several resistance genes. The second most frequent
profile, P12, is shared by three isolates belonging to CC5 and CC22. Isolates of the same
clonal complex show a high variety of plasmid profiles. For example, isolates of CC5, CC8,
and CC22 have four different plasmids profiles each (Figure 2).
Of the six pairs of isolates recovered from two anatomical sites of the same patient,
only one pair was assigned to two distinct PFGE types. Four pairs of isolates were indistin-
guishable by PFGE, while the remaining pair included subtypes of the same PFGE type.
However, different phenotypical or genotypical trait(s) were observed within each pair
except one (Figure 2). Isolates of three pairs differed in plasmid content, while two pairs
of isolates differed in terms of resistance profile and/or resistance determinants. Another
pair of isolates displayed different resistance profile and determinants although sharing
the same plasmid profile.
3. Discussion
S. aureus is a leading cause of bacterial infections not only in healthcare settings but also
in the community, many of which are caused by MRSA and MDR strains [2]. According
to the most recent data of EARS-Net (European Antimicrobial Resistance Surveillance
Network), in 2019, the prevalence of MRSA in bloodstream infections in Portugal was
34.8%. Even though this value has been decreasing over the last decade, it was still the fifth
highest registered in Europe [24].
A high frequency of antibiotic resistance was observed in this collection. All isolates
except one were resistant to at least one class of antibiotics, mainly β-lactams, and nearly
half (44.1%) were MDR, which was unexpected considering they were not from hospitalized
patients. However, these isolates were collected from ambulatory patients who could have
been under antibiotic therapy or could have had recent contact with hospitals and that
might explain the high rates of resistance observed. The 44.1% rate of MRSA identified
is higher than the MRSA rates reported in the community (21.6%) in Portugal [19] and in
children affected by SSTIs attending a pediatric emergency in Lisbon area (8.6%) [25] in
years close to the year of collection of these isolates and is closer to the values observed
in hospitals (47.4%) for 2014 [26]. On the other hand, the fact that these patients used
laboratory services suggests that these may reflect more complex infections, which may
explain the high frequencies of resistance observed [27]. Of the 15 MRSA, 11 (73.3%) were
also MDR and the most common pattern was resistance to β-lactams, fluoroquinolones,
macrolides, and lincosamides, which is a profile frequently observed in hospital-acquired
MRSA (HA-MRSA) [19,20]. Previous studies have shown that there is a high prevalence of
HA-MRSA strains in the community in our country, due to dissemination of these strains
from the hospital [19–21]. The molecular analysis revealed that most of the isolates studied
(16/34, 47.1%) presented genetic backgrounds related to hospital-associated lineages, such
as CC5 and CC22, which were the predominant HA-MRSA lineages in Portugal during this
period, identified in nosocomial or community isolates [18,19]. This finding, together with
the use of community laboratory services to treat possible resilient and complex infections,
may explain the high frequency of resistance observed in this collection. Regarding MSSA
strains, only four strains showed an MDR profile (4/19, 21%). This observed rate of MDR
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strains is higher than previously reported for other MSSA collected from the community in
Portugal [25,28].
With the exception of ST278 and the two new STs, all the other strain lineages identified
in this work have been found in other studies in Portugal, with ST8 being the most frequent
CA-MRSA clone, while ST30 and ST72 were the most prevalent MSSA clones [18,19,29].
ST278 belongs to CC45 and has been reported in the USA as a MSSA clone [30,31]. Strains
of CC45 are prevalent in Portugal [18,19,29], but as far as we know, ST278 has not been yet
reported in our country. We have also identified two new STs, ST6531, a SLV of ST5, and
the singleton ST6564.
Although the S. aureus studied were isolated from patients with SSTIs, a low fre-
quency of resistance was observed toward topical antibiotics, particularly to neomycin
and fusidic acid, which are some of the most commonly used for the treatment of SSTIs
in the community [7]. Only two isolates (5.9%) were resistant to fusidic acid, and only
one isolate (2.9%) did not show inhibition zone to neomycin or bacitracin. The current
rates of resistance to fusidic acid reported in the literature for SSTIs-associated S. aureus
vary geographically, ranging from over 30% in Africa [32] to much lower rates, 2 to 6% in
Asia or South America [33,34]. These low levels of resistance to fusidic acid are similar to
the ones detected in other contemporary studies in Portugal [19]. The rates of resistance
to neomycin and bacitracin in our collection are lower than the ones reported for other
CA-MRSA from SSTIs [34]. However, a higher frequency of resistance was detected to-
ward clindamycin (35.3%), an antibiotic also recommended for topical treatment of these
infections, in comparison with other CA-MRSA from SSTIs [35,36].
Antibiotic-resistance determinants were identified in all isolates presenting phenotypic
resistance (Table 1). The distribution of the fusidic-acid-resistance determinants in S. aureus
reported in the literature is variable. While some studies report that fusB and fusC are the
most prevalent genes [37], others report fusA mutations as the most common mechanism
of fusidic-acid resistance [38]. In this study, only two isolates were resistant to fusidic acid.
One of these had three mutations in the fusA gene, two of which (A71V and H457Q) already
associated with resistance to this antibiotic [39–41], while the third mutation found, G476C,
was described for the first time in this work and could also be contributing to fusidic-acid
resistance. The other isolate resistant to fusidic acid carried the fusC gene. This is an MSSA
that belongs to ST5. Several studies have shown that fusC gene can be located in SSCmec
cassettes, with or without mecA gene [42,43].
Screening for mutations in fluoroquinolone-resistant representative isolates identified
several patterns of mutations in the QRDR regions of GrlA and GyrA (namely, GrlA
S80Y, GyrA S84L; GrlA S80F, GyrA E88K; GrlA S80Y E84G, GyrA E88K; and GrlA S80F
GyrA S84L) already associated with high level resistance to these antibiotics [44,45]. These
patterns of QRDR mutations were also detected in an earlier study from S. aureus clinical
isolates in Lisbon [46]. The GrlA S80F and GyrA S84L mutations are the most commonly
described in the literature [47–51] and are characteristic of ST22 and some ST8 lineages [51].
In our study, only one isolate carried both mutations and belonged to ST22. The GyrA S84L
mutation was also found in one isolate of ST8. The GrlA E84G and S80Y and GyrA E88K
mutations are also described in some studies [50,51] but appear to be less frequent. Besides
these mutations, the activity of chromosomally-encoded MDR efflux pumps might also be
contributing to fluoroquinolone resistance. A subset of fluoroquinolone-resistant isolates
presented increased efflux activity of EtBr, a common substrate of MDR efflux pumps like
NorA/B/C and MepA, which also extrude fluoroquinolones. No significant reduction in
CIP MICs was observed in the presence of EIs, yet the effect of these compounds may be
potentially hindered by the presence of QRDR mutations. The absence in this collection
of the plasmid-encoded efflux pump genes qacA/B or smr indicates that the higher EtBr
efflux activity detected is probably due to the overexpression of chromosomal efflux pump
genes such as norA/B/C or mepA [13,46]. In the future this, hypothesis can be confirmed be
quantifying the expression levels of these genes by RT-qPCR.
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Plasmid profiling revealed a high proportion of plasmid-bearing isolates (82.4%) and
a high diversity of plasmids, with 17 different profiles identified distributed amongst
14 clonal lineages. Most isolates carried a large plasmid, potentially associated with
determinants for resistance to β-lactams, macrolides, lincosamides, and aminoglycosides
(Figure 2). These results are similar to the ones found in a previous study that analyzed the
plasmid content of a collection of 53 S. aureus isolated from a hospital in Lisbon between
2006 and 2007 [52]. The proportion of plasmid-bearing isolates in that study was 83%,
and most isolates carried a large plasmid that was frequently associated with resistance
to β-lactams, macrolides, and lincosamides. Other studies have also demonstrated that
large plasmids are quite common in S. aureus and that they can carry several resistance
determinants associated with resistance to the classes of antibiotics mentioned above [16].
The occurrence of PVL is linked to the bacteriophage ϕSa2 and generally associated
with community-acquired MRSA (CA-MRSA), being traditionally considered a marker
for the identification of CA-MRSA isolates [53], although some CA-MRSA strains do not
produce this toxin. Its prevalence in HA-MRSA isolates, albeit lower, has been documented
in several countries [54]. PVL is also strongly linked with S. aureus isolates collected from
skin infections [53,54]. The overall rate of 20.6% of PVL-positive isolates in our set of
S. aureus associated with SSTIs is lower than the ones reported from children with SSTI
attending a pediatric emergency (37%) [25] but higher than the ones reported for other
MSSA, CA-MRSA, or HA-MRSA collections in Portugal [19,22,55,56], albeit most of these
other collections are not exclusively associated with skin infections. PVL carriage in our set
of MRSA isolates appears restricted to the ST8-agrI clonal lineage, as found in a previous
study by Tavares and colleagues [19]. Interestingly, the single MSSA ST8 isolate of our
collection did not harbor PVL. The PVL-positive MSSA detected in our collection belong to
the genetic backgrounds ST30-agrIII and ST152-agrI, different from the ones reported in
that earlier study [19]. However, PVL-positive ST30 isolates were also detected in children
with SSTIs attending a pediatric emergency [25]. The ST8 and ST30 clonal lineages were
frequently encountered in isolates from the community and less frequently associated with
nosocomial isolates [19,20].
In this study, we performed a phenotypic and genotypic characterization of a collection
of S. aureus isolated from SSTIs in ambulatory patients. Although this can be considered a
relatively small sample, this is a convenience collection that represents the diversity of the
population affected by SSTIs in an ambulatory setting over a five-months period where the
only condition criteria for inclusion of the S. aureus isolates was to be SSTI-related. The
genetic diversity of this collection was demonstrated by the high value of the Simpson’s
index (SID of 0.92).
4. Materials and Methods
4.1. Bacterial Isolates
The study comprised a collection of 34 S. aureus isolates associated with SSTIs of
28 ambulatory patients. Of the 34 isolates, 31 were collected from wounds (legs, n = 17;
foot, n = 5; armpit, n = 3; ear, n = 1; and from unidentified sites, n = 4), and three were
collected from ulcers. Six pairs of isolates (n = 12) were collected from different anatomical
sites (right/left leg, n = 6; right/left armpit, n = 2; ear/leg, n = 2; and unidentified sites,
n = 2) of six patients. The isolates were collected between February and June of 2014 at
a community clinical diagnostic laboratory in Lisbon, Portugal. All isolates were grown
in tryptic soy broth (TSB) (Oxoid™, Hampshire, UK), with shaking or tryptic soy agar
(TSA) (Oxoid™) at 37 ◦C. Species identification was confirmed by amplification of the nuc
gene following the protocol described by Poulsen and colleagues [57], using the primers
described in Table S1 of Supplementary Data.
4.2. Antimicrobial Susceptibility Testing
Antimicrobial susceptibility was determined for a panel of 24 antibiotics by disk diffu-
sion in Mueller-Hinton agar (MHA, Oxoid™), according to the EUCAST guidelines [58].
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Antibiotics discs were obtained from Oxoid™. The following antibiotic discs (antibiotic
content per disc) were used: penicillin (PEN, 1 U), oxacillin (OXA, 1 µg), cefoxitin (CXI,
30 µg), ceftaroline (CPT, 5 µg), ciprofloxacin (CIP, 5 µg), moxifloxacin (MOX, 5 µg), gentam-
icin (GEN, 10 µg), kanamycin (KAN, 30 µg), tobramycin (TOB, 10 µg), neomycin (NEO,
30 µg), amikacin (AMI, 30 µg), tetracycline (TET, 30 µg), minocycline (MIN, 30 µg), tigecy-
cline (TIG, 15 µg), chloramphenicol (CHL, 30 µg), erythromycin (ERY, 15 µg), clindamycin
(CLI, 2 µg), quinupristin/dalfopristin (QD, 15 µg), linezolid (LIN, 10 µg), trimethoprim-
sulfamethoxazole (TRS, 25 µg), rifampicin (RIF, 5 µg), bacitracin (BAC, 10 U), fusidic acid
(FUS, 10 µg), and mupirocin (MUP, 200 µg). The D-zone test was performed for detection
of inducible clindamycin resistance, and the penicillin inhibition zone was examined to
detect production of β-lactamases. Susceptibility testing to ceftaroline was performed
for MRSA isolates only. Susceptibility to retapamulin (RET) was evaluated by determina-
tion of MICs by the two-fold microdilution method with cation-adjusted Mueller-Hinton
broth (CAMHB, Oxoid™), according to the Clinical and Laboratory Standards Institute
(CLSI) guidelines [59]. Retapamulin was acquired in powder form from Sigma-Aldrich
(St. Louis, MO, USA), dissolved in dimethyl sulfoxide, and diluted in water with 10% β-
cyclodextrin [60]. The reference strain S. aureus ATCC®29213™ was used as quality control.
Isolates resistant to one antibiotic of at least three classes of antibiotics were considered
multidrug resistant [61].
4.3. Detection of Resistance Genes by PCR
Total DNA was extracted from each isolate by the boiling method as described by
Alexopoulou and colleagues [62]. All isolates were screened by PCR for the presence of the
resistance genes mecA and blaZ and plasmid-encoded efflux pump genes qacA/B and smr
(reduced susceptibility to biocides and EtBr). Isolates presenting phenotypic resistance to
antibiotics were also screened for the presence of the genes erm(A), erm(B), erm(C), msr(A),
mph(C), vga(A), vga(C) (resistance to macrolides, lincosamides, and streptogramins), aadD,
aph(3′)-IIIa, aacA-aphD (resistance to aminoglycosides), fusB, and fusC (resistance to fusidic
acid) using the primers described in Table S1 of Supplementary Data.
4.4. Screening of Mutations in grlA, gyrA, and fusA Genes
Mutations in the QRDRs of grlA and gyrA genes associated with fluoroquinolone
resistance were screened for representative isolates, chosen according to their PFGE types.
Mutations in the fusA gene were screened for isolates presenting resistance to fusidic
acid. The primers used for amplification and sequencing of grlA, gyrA, and fusA genes are
described in Table S1. Amplification products were purified using the kit NZYGelpure
(NZYTech, Lisboa, Portugal) and sequenced. Sequences were analyzed using the programs
SnapGene Viewer (GSL Biotech; available at snapgene.com) and blastx (NCBI, Bethesda,
MD, USA).
4.5. Evaluation of Efflux Activity
The presence of increased efflux activity was evaluated by (i) determining the EtBr
MIC [63] and (ii) determination of EtBr and CIP MICs in the presence of the EIs TZ and
VER [23,46]. MICs of EtBr, CIP, TZ, and VER (Sigma-Aldrich) were determined by the two-
fold broth microdilution method. Briefly, from overnight cultures, a cellular suspension
equivalent to McFarland 0.5 was prepared in CAMHB and aliquoted in 96-well plates
containing two-fold dilutions of the compound to be tested. Plates were incubated at
37 ◦C for 18 h, and the MIC registered as the lowest concentration of compound that
inhibited visible growth. EtBr and CIP MICs were then redetermined in the presence of TZ
and VER at 12.5 µg/mL and 400 µg/mL, respectively, corresponding to a subinhibitory
concentration (1/2 MIC) [23]. The 96-well plates were prepared as described previously,
except for the addition of a 0.01 mL aliquot of TZ or VER to each well prior to inoculation
of the plate. Each assay was performed in duplicate. A four-fold, or higher, decrease in
MICs values in the presence of EIs is indicative of inhibition of efflux activity [23].
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4.6. Plasmid DNA Extraction and Profiling
Plasmid DNA of each isolate was extracted with the kit NZYMiniprep (NZYTech),
adding 35 µg/mL of lysostaphin (Sigma-Aldrich) in the cell lysis step with buffer A1,
followed by an incubation at 37 ◦C for 90 min. For isolates carrying a single plasmid,
plasmid DNA was digested with 10 U of the enzyme EcoRI (NZYTech). The reaction
mixture was incubated at 37 ◦C for 90 min and inactivated at 65 ◦C for 20 min. Restriction
profiles were analyzed by 1% (w/v) agarose gel electrophoresis for 90 min.
4.7. Detection of lukSF Genes
The presence of the determinants lukF-PV and lukS-PV encoding PVL was screened
by PCR, using the primers described in Table S1 of the Supplementary Data.
4.8. Molecular Typing
All isolates were characterized by PFGE. SmaI-PFGE was performed as previously
described [64], and macrorestriction profiles were analyzed with the Bionumerics software
v 7.6 using the Dice coefficient and dendrograms built based on the UPGMA algorithm,
considering a band tolerance of 1% and an optimization of 0.5%. Isolates presenting
macrorestriction profiles with a similarity ≥81% or ≥97% were considered as belonging to
the same PFGE type or subtype, respectively [65]. The genetic diversity of the collection
was calculated, based on PFGE types, by Simpson’s index of diversity with a confidence
interval of 95% [66].
A subset of isolates representative of each PFGE type was further analyzed by MLST.
Isolates sharing the same PFGE type or subtype were considered as belonging to the
same ST. Internal fragments of the seven housekeeping genes arcC, aroE, glpF, gmk, pta,
tpi, and yqiL were amplified by PCR and sequenced using the primers and conditions
previously described [67,68]. Allelic profiles and STs were obtained from MLST database
(PubMLST.org (accessed on 28 December 2020). New alleles and ST profiles were submitted
to PubMLST for validation and allele/ST assignment. The relationship between clonal
lineages were inferred with the PHYLOViZ freeware using the goeBurst algorithm [69].
agr typing of all isolates was performed according to the protocol described by Lina
and colleagues [70]. The set or primers used for agr typing is described in Table S1.
5. Conclusions
This work demonstrates a high prevalence of antibiotic resistance in S. aureus of SSTIs
from outside the hospital environment, correlating it with the presence of several antibiotic-
resistance determinants and a high prevalence of PVL-positive isolates, assigned to three
MSSA (ST152-agrI and ST30-agrIII) and four MRSA (ST8-agrI) isolates. This study also
highlights the phenotypic and genotypic variability that may be present in S. aureus isolates
causing infection in distinct anatomical sites of the same patient. The high diversity of
plasmids identified in this collection demonstrates the important role these MGEs have in
the transmission of antimicrobial resistance in S. aureus and the relevance of studying these
elements to further prevent the dissemination of MDR strains.
Supplementary Materials: The following is available online at https://www.mdpi.com/2079-6382/
10/4/345/s1, Table S1: Primers used in this study.
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